Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Antithrombotic therapy in atrial arrhythmia].

Ariel Cohen1

  • 1Service de cardioloqie, CHU Saint-Antoine, 75571 Paris Cedex 12. ariel.cohen@sat.ap-hop-paris.fr

La Revue Du Praticien
|May 12, 2004
PubMed
Summary

Oral anticoagulants effectively prevent stroke in atrial arrhythmias but carry bleeding risks. Newer direct anti-thrombin therapies show promise as safer alternatives for high-risk patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Four-Chamber Myocardial Strain to Predict Mortality in Pulmonary Embolism.

The Canadian journal of cardiology·2026
Same author

Increased mortality in myocardial infarction after COVID-19 infection: more and more convincing data.

European journal of preventive cardiology·2026
Same author

[Patient education in heart failure].

La Revue du praticien·2026
Same author

Development Parameters of the Decision Aid Rule-Based Evaluation and Support Tool (REST) for Optimizing the Resources of an Information Extraction Task.

Studies in health technology and informatics·2026
Same author

Intensive patient education by specialized nurses taking care of patients with heart failure: Results of the EDUSTRA-HF trial on the primary endpoint.

Archives of cardiovascular diseases·2026
Same author

A Comprehensive Assessment of Cancer Patient Performance Status Documentation in a Large, Multicentre Hospital System.

Journal of evaluation in clinical practice·2026

Area of Science:

  • Cardiology
  • Pharmacology

Context:

  • Atrial arrhythmias pose a significant risk of thrombo-embolic events, particularly cerebrovascular accidents (stroke).
  • Oral anticoagulants are proven effective in reducing stroke risk, outperforming anti-platelet drugs.
  • Vitamin K antagonists (e.g., warfarin) have a notable annual hemorrhage risk (around 5%), limiting their use in elderly or high-risk patients.

Purpose:

  • To review the efficacy and risks of oral anticoagulants for preventing stroke in atrial arrhythmias.
  • To explore alternative therapeutic options, such as direct anti-thrombin agents, for patients where warfarin is contraindicated or poses excessive risk.
  • To discuss the management of thrombo-embolic risk associated with cardioversion in atrial arrhythmia patients.

Summary:

  • Oral anticoagulants significantly reduce cerebrovascular accident risk in atrial arrhythmias compared to anti-platelet agents.
  • The risk of serious hemorrhage with warfarin restricts its use, leading to under-prescription in the elderly.
  • Direct anti-thrombin agents like ximelagatran present promising alternatives, and anticoagulant therapy is crucial for managing cardioversion risks.

Impact:

  • Highlights the clinical challenge of balancing stroke prevention with bleeding risk in atrial arrhythmia management.
  • Underscores the need for safer anticoagulant alternatives, particularly for elderly and high-risk populations.
  • Informs clinical practice regarding the appropriate use of anticoagulation and the potential of novel therapeutics in managing atrial arrhythmias and associated thrombo-embolic complications.

Related Experiment Videos